BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26080829)

  • 21. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder.
    Han Y; Liu Y; Nie L; Gui Y; Cai Z
    Urology; 2013 Jan; 81(1):209.e1-7. PubMed ID: 23153939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy.
    Ben Shachar B; Feldstein O; Hacohen D; Ginsberg D
    Mol Cancer Res; 2010 Mar; 8(3):363-72. PubMed ID: 20197383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Suppression of insulin-like growth factor-1 receptor by RNA interference inhibits cell growth in vitro and induces chemosensitization of HO8910PM cell to cisplatin].
    Gao H; Shi J; Ge SF; DI W
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):45-9. PubMed ID: 18366933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
    Li JR; Cheng CL; Yang CR; Ou YC; Wu MJ; Ko JL
    Toxicol Lett; 2013 Jul; 220(3):267-76. PubMed ID: 23651616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer.
    Tada Y; Yokomizo A; Shiota M; Tsunoda T; Plass C; Naito S
    Int J Oncol; 2011 Sep; 39(3):727-33. PubMed ID: 21617853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway.
    Wang Z; Ma LJ; Kang Y; Li X; Zhang XJ
    Oncol Rep; 2015 Mar; 33(3):1097-106. PubMed ID: 25573172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells.
    Ho JN; Byun SS; Lee S; Oh JJ; Hong SK; Lee SE; Yeon JS
    J Urol; 2015 Mar; 193(3):1016-22. PubMed ID: 25229559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
    Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.
    Myers AL; Lin L; Nancarrow DJ; Wang Z; Ferrer-Torres D; Thomas DG; Orringer MB; Lin J; Reddy RM; Beer DG; Chang AC
    Oncotarget; 2015 Sep; 6(28):25897-916. PubMed ID: 26317790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis.
    Tahmatzopoulos A; Sheng S; Kyprianou N
    Oncogene; 2005 Aug; 24(34):5375-83. PubMed ID: 16007219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line.
    Kim JK; Kim KD; Lee E; Lim JS; Cho HJ; Yoon HK; Cho MY; Baek KE; Park YP; Paik SG; Choe YK; Lee HG
    Cancer Lett; 2004 Aug; 212(1):61-70. PubMed ID: 15246562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
    Chang FL; Ling YF; Lai MD
    Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Bcl-2 on apoptosis and transcription factor NF-κB activation induced by adriamycin in bladder carcinoma BIU87 cells.
    Zhang GJ; Zhang Z
    Asian Pac J Cancer Prev; 2013; 14(4):2387-91. PubMed ID: 23725146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells.
    Cho HJ; Kim JK; Kim KD; Yoon HK; Cho MY; Park YP; Jeon JH; Lee ES; Byun SS; Lim HM; Song EY; Lim JS; Yoon DY; Lee HG; Choe YK
    Cancer Lett; 2006 Jun; 237(1):56-66. PubMed ID: 16009487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The influence and mechanisms of purple sweet potato anthocyanins on the growth of bladder cancer BIU87 cell].
    Li WL; Ji GH; Zhang XZ; Yu HY
    Zhonghua Yi Xue Za Zhi; 2018 Feb; 98(6):457-459. PubMed ID: 29429260
    [No Abstract]   [Full Text] [Related]  

  • 38. ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines.
    Li W; Jie Z; Li Z; Liu Y; Gan Q; Mao Y; Wang X
    Mol Med Rep; 2014 Jun; 9(6):2423-8. PubMed ID: 24699918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity.
    Ishiguro H; Kawahara T; Zheng Y; Kashiwagi E; Li Y; Miyamoto H
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):249-55. PubMed ID: 24880571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multikinase inhibitor motesanib enhances the antitumor effect of cisplatin in cisplatin‑resistant human bladder cancer cells via apoptosis and the PI3K/Akt pathway.
    Ho JN; Byun SS; Lee SE; Youn JI; Lee S
    Oncol Rep; 2019 Apr; 41(4):2482-2490. PubMed ID: 30816494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.